^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    obrindatamab (MGD009)

    i
    Other names: MGD009
    Associations

    News

    Trials
    Company:
    MacroGenics
    Drug class:
    CD3 agonist, B7-H3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors suggesting potential anti-B7-H3 therapy in triple-negative breast cancer (SABCS 2023)
    Multiple anti-B7-H3 therapies has been raised, such as DS-7300, MGA271, MGD009, and B7-H3 chimeric antigen receptor T-cell immunotherapy (CAR-T)...In the durvalumab-dependent cohort, paclitaxel-dependent cohort, anthracycline-dependent cohort, and our recruited NAT cohort, the B7-H3highPDL1low subgroup exhibited the lowest therapeutic response. Overall, this research provides a novel subtyping strategy based on the combination of B7-H3/PD-L1 expression that could potentially be applied to predict the therapeutic responses in TNBC, and suggests a potential biomarker-guided anti-B7-H3 therapy. Based on the classifier, we can select potential beneficiaries to deliver personalized medical services.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule)
    |
    PD-L1 expression • CD276 expression • PD-L1-L
    |
    Imfinzi (durvalumab) • paclitaxel • ifinatamab deruxtecan (DS-7300) • enoblituzumab (MGA271) • obrindatamab (MGD009)
    almost2years
    B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer? (PubMed, Int J Mol Sci)
    In addition to its role in immune modulation, B7-H3 also promotes pro-tumorigenic functions such as tumor migration, invasion, metastases, resistance, and metabolism. In this review, we will provide an overview of this newly characterized immune checkpoint molecule and its development in the management of metastatic NSCLC.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule)
    |
    CD276 expression
    |
    ifinatamab deruxtecan (DS-7300) • vobramitamab duocarmazine (MGC018) • enoblituzumab (MGA271) • obrindatamab (MGD009)
    over2years
    MGD009/MGA012 Combination in Relapsed/Refractory Cancer (clinicaltrials.gov)
    P1, N=25, Completed, MacroGenics | Active, not recruiting --> Completed
    Trial completion • Combination therapy
    |
    CD276 (CD276 Molecule)
    |
    PD-L1 expression • CD276 expression
    |
    Zynyz (retifanlimab-dlwr) • obrindatamab (MGD009)
    over2years
    MGD009/MGA012 Combination in Relapsed/Refractory Cancer (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, MacroGenics | Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD276 (CD276 Molecule)
    |
    PD-L1 expression • CD276 expression
    |
    Zynyz (retifanlimab-dlwr) • obrindatamab (MGD009)
    over3years
    MGD009/MGA012 Combination in Relapsed/Refractory Cancer (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, MacroGenics | Trial completion date: Dec 2022 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD276 (CD276 Molecule)
    |
    PD-L1 expression • CD276 expression
    |
    Zynyz (retifanlimab-dlwr) • obrindatamab (MGD009)